Wall St. provides estimates for future stock prices of Eli Lilly from 2025 to 2030 based on projected revenue and net income.

Eli Lilly stock could soar 140% by 2028 as millions of Americans begin to take their GLP-1 weight loss drugs, according to Goldman Sachs. The firm estimated that if all GLP-1 trials succeed, 68 ...

Both Eli Lilly LLY and Merck MRK are major players in the U.S. pharmaceutical industry, developing and commercializing ...

Eli Lilly's weight loss drugs, especially Zepbound and Mounjaro, have driven impressive revenue growth. Click here to read an ...

In the latest quarter, 7 analysts provided ratings for Eli Lilly LLY +1.30% Get Free Report , showcasing a mix of bullish and ...

Eli Lilly LLY 0.30 % increase; green up pointing triangle cut its outlook for fourth-quarter revenue as the market for drugs that increase insulin levels grew slower than expected, but the company ...

Lilly affirmed its full-year revenue guidance, but lowered its profit forecasts. Last quarter , it said it expected 2025 revenue between $58.0 to $61.0 billion, with EPS from $22.05 to $23.55, and ...

Eli Lilly (NYSE: LLY) may seem like an expensive stock to invest in right now. Its $720 billion market capitalization also means it's the most valuable healthcare stock in the world. It's one that ...

Eli Lilly's strong growth prospects make it a top investment. That's why, while the stock may appear expensive today, it can still be a great buy in the long run as Eli Lilly's business is poised ...

Eli Lilly (LLY 14.56%) has been on an epic run of late. Thanks to the excitement over its Alzheimer's disease and weight-loss assets, Lilly's shares have clobbered the broader markets over the ...

Chris Shibutani, an analyst from Goldman Sachs, maintained the Hold rating on Eli Lilly & Co (LLY – Research Report). The associated price target is $650.00. Geoff Meacham has given his Hold ...

By Owen Tucker-Smith . Eli Lilly cut its outlook for fourth-quarter revenue as the market for drugs that increase insulin levels grew slower than expected, but the company sees healthy growth in ...